- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04991402
Obesogenic Origins of Maternal and Child Metabolic Health Involving Dolutegravir (ORCHID)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up as part of the preferred 1st-line ART regimen. However, DTG has recently been implicated as an obesogen that is associated with increased weight and adipose tissue gain compared to other antiretroviral agents. Obesity in pregnancy is associated with poor health outcomes for both mother and child as pregnancy is a critical period during which exposures leading to alterations in metabolic health may influence not only long-term maternal health but also fetal, neonatal, and ultimately child health. To address the gap of knowledge on the obesogenic effects of DTG in pregnant women living with HIV (WLHIV) and their children, this prospective cohort study will investigate the impact of DTG in pregnancy and its obesogenic effects on the metabolic health of WLHIV and their children, compared to women without HIV and their children. Up to 1900 pregnant women will be enrolled and followed to delivery and then as mother-infant pairs through 5 years postpartum (ORCHID study main cohort).
Additionally, a nested cohort study will be conducted and enroll a subset of 108 pregnant women who are currently being followed as part of the parent ORCHID study's main cohort. This substudy will explore the associations of DTG (initiating and continuing DTG use during pregnancy) with longitudinal perturbations in subcutaneous adipose tissue (SAT) function and changes in weight and adipose tissue mass in pregnancy through 2 years postpartum in WLHIV using a comparison group of HIV-seronegative women. They will been seen at up to 3 different time points (up to 2 visits during pregnancy and 1 visit postpartum) separate from the parent study to undergo a fat biopsy procedure to extract SAT samples.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Landon Myer, PhD, MBBCH
- Phone Number: 021 406-6661
- Email: landon.myer@uct.ac.za
Study Locations
-
-
-
Cape Town, South Africa
- Recruiting
- Gugulethu Community Health Center
-
Cape Town, South Africa
- Recruiting
- Mitchell's Plain Community Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For All Women:
- Confirmed pregnancy based on urine pregnancy test with viable gestation ≤ 18 weeks and 6 days by ultrasound
- Age 16 years or older
- No stated intention to relocate permanently outside of Cape Town through 2 years postpartum
For Women Living with HIV (WLHIV):
• Confirmed HIV infection based on medical record review and/or HIV antibody testing during antenatal care
For WLHIV continuing DTG in pregnancy (cDTG):
• Confirmed use of tenofovir 300mg + lamivudine 300mg/emtricitabine 200mg + dolutegravir 50mg (TLD) on the day of assessment
For WLHIV initiating DTG in pregnancy (iDTG):
• Planned initiation of TLD on the day of assessment or within 1 week thereafter, including women switching from efavirenz-based regimen
For women without HIV (HIV-):
• Confirmed HIV status by HIV antibody testing during antenatal care
Exclusion Criteria:
- In the opinion of the investigator, unable to provide informed consent due to mental or physical condition
- In the opinion of the investigator, unable to undertake BodPod assessment due to mental (eg, active psychosis or severe claustrophobia) or physical condition (eg, weight >250 kg).
- Currently being treated for any form of diabetes mellitus or hypertensive disorder based on participant self-report and medical record review
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV uninfected pregnant women
Pregnant women not living with HIV
|
|
Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)
Pregnant women living with HIV initiating DTG-based ART in pregnancy at the 1st visit
|
This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy. This is considered standard of care. |
Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)
Pregnant women living with HIV already on DTG-based ART prior to enrollment and continuing DTG use through pregnancy
|
This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy. This is considered standard of care. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in adiposity in the child between HIV positive mothers and HIV negative mothers
Time Frame: <2 weeks, up to 2 years of age
|
Adiposity will be measured as the main indicator of metabolic health.
This outcome focuses on the comparison between children whose mothers are HIV positive and those whose mothers are HIV negative.
Differences in adipose accrual and/or retention will calculated as the difference in adipose (% per week) between the timepoint in question and baseline.
|
<2 weeks, up to 2 years of age
|
Changes in adiposity in the child between iDTG and cDTG mothers
Time Frame: <2 weeks, up to 2 years of age
|
Adiposity will be measured as the main indicator of metabolic health.
This outcome focuses on the comparison between children whose mothers initiated DTG during pregnancy and those whose mothers continued DTG during pregnancy.
Differences in adipose accrual and/or retention will calculated as the difference in adipose (% per week) between the timepoint in question and baseline.
|
<2 weeks, up to 2 years of age
|
Difference in excess gestational weight gain between pregnant women living with HIV and HIV negative pregnant women
Time Frame: <18 weeks (baseline), 32-34 weeks
|
This is to measure the difference in gestational weight gain between pregnant women living with HIV and HIV negative pregnant women during pregnancy in kg.
The women will be weighed by a scale at the study visit.
|
<18 weeks (baseline), 32-34 weeks
|
Difference in gestational weight gain between iDTG and cDTG pregnant women
Time Frame: <18 weeks (baseline), 32-34 weeks
|
This is to measure the difference in gestational weight gain between pregnant women initiating DTG during pregnancy (iDTG) and pregnant women continuing DTG during pregnancy (cDTG) in kg.
The mothers will be weighed by a scale at the study visit.
|
<18 weeks (baseline), 32-34 weeks
|
Change in adipose tissue mass compared between pregnant women living with HIV and HIV negative pregnant women
Time Frame: <18 weeks (baseline), 32-34 weeks
|
Comparison of percent adipose tissue mass per week between pregnant women living with HIV and HIV negative pregnant women during pregnancy.
|
<18 weeks (baseline), 32-34 weeks
|
Change in adipose tissue mass compared between iDTG and cDTG mothers
Time Frame: <18 weeks (baseline), 32-34 weeks
|
Comparison of percent adipose tissue mass per week between pregnant women initiating DTG during pregnancy (iDTG) and pregnant women continuing DTG during pregnancy (cDTG).
|
<18 weeks (baseline), 32-34 weeks
|
Differences in maternal metabolic health post-partum between mothers living with HIV and HIV negative mothers
Time Frame: <18 weeks antenatal, 24 weeks postpartum, and 24 months postpartum
|
Adiposity will be measured as the main indicator of metabolic health.
This outcome focuses on the comparison between mothers living with HIV and HIV negative mothers during pregnancy.
Differences in adipose accrual and/or retention will calculated as the difference in adipose (% per week) between the timepoint in question and baseline.
|
<18 weeks antenatal, 24 weeks postpartum, and 24 months postpartum
|
Differences in maternal metabolic health post-partum between iDTG and cDTG mothers
Time Frame: <18 weeks antenatal, 24 weeks postpartum, and 24 months postpartum
|
Adiposity will be measured as the main indicator of metabolic health.
This outcome focuses on the comparison between mothers initiating DTG during pregnancy and mothers continuing DTG during pregnancy.
Differences in adipose accrual and/or retention will calculated as the difference in adipose (% per week) between the timepoint in question and baseline.
|
<18 weeks antenatal, 24 weeks postpartum, and 24 months postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in subcutaneous adipose tissue (SAT) function
Time Frame: <18 weeks (baseline), 32-34 weeks antenatal, 24 months postpartum
|
The SAT sample will reveal information regarding adipocyte hypertrophy, hypoxia, increased fibrosis and inflammation, decreased SAT mitochondrial respiration, and any altered metabolome/lipidome.
|
<18 weeks (baseline), 32-34 weeks antenatal, 24 months postpartum
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elaine J. Abrams, MD, ICAP at Columbia University
- Principal Investigator: Jennifer Jao, MD, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Obesity
- Pediatric Obesity
- Pregnancy Complications
- Obesity, Maternal
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Anti-Retroviral Agents
- Dolutegravir
Other Study ID Numbers
- AAAT6112
- 1R01HD104599 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Dolutegravir-based antiretroviral therapy
-
University of ZurichUnknownTreatment Efficacy | Monotherapy | Dolutegravir | Primary HIV InfectionSwitzerland
-
MRC/UVRI and LSHTM Uganda Research UnitJanssen PharmaceuticalsRecruitingHIV-1-infectionSouth Africa, Kenya, Uganda
-
Ohio State UniversityNational Institute on Drug Abuse (NIDA)Completed
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Babafemi TaiwoViiV HealthcareCompletedHIV InfectionUnited States
-
Centers for Disease Control and PreventionThe AIDS Support Organization; British Medical Research CouncilCompleted
-
Rockefeller UniversityAaron Diamond AIDS Research CenterCompletedHIV InfectionsUnited States
-
Janssen-Cilag Farmaceutica Ltda.Completed
-
Elizabeth Anne ThieleAjinomoto Co., Inc.; Ajinomoto USA, INC.Not yet recruitingDrug Resistant Epilepsy | Refractory EpilepsyUnited States
-
National Center for Research Resources (NCRR)Elizabeth Glaser Pediatric AIDS FoundationCompleted